B-Cell Lymphomas Coverage from Every Angle

Recent News

Long-Term Update on Upfront Rituximab Versus ‘Watch and Wait’ in Follicular Lymphoma
Role of MRD in Rituximab Maintenance for Older Patients With Mantle Cell Lymphoma
Combination of Zandelisib Plus Zanubrutinib in Treatment of B-Cell Malignancies
Adding Acalabrutinib to Combination Therapy for Mantle Cell Lymphoma
Priority Review Granted by the FDA for Glofitamab in Treatment of Large B-Cell Lymphoma
ASH 2022: Phase II Study Results With Mosunetuzumab in Resistant Follicular Lymphoma
ASH 2022: Updated ELARA Trial Results of Tisagenlecleucel Therapy for Advanced Follicular Lymphoma
ASH 2022: Does Addition of Lenalidomide Boost Rituximab Efficacy in Mantle Cell Lymphoma?
FDA Brief: Mosunetuzumab Granted Approval in Treatment of Resistant Follicular Lymphoma
ASH 2022: Does Time to Relapse Affect Response to Second-Line Chemotherapy in DLBCL?
ASH 2022: Can Ibrutinib Combination Replace ASCT for Some Younger Patients With Mantle Cell Lymphoma?
ASH 2022: POLARIX Trial Focuses on ctDNA for Risk Profiling in Diffuse Large B-Cell Lymphoma
ASH 2022: Glofitamab Monotherapy for Resistant Mantle Cell Lymphoma
ASH 2022: Could IRF4 Become a Prognostic Marker in Follicular Lymphoma?
Axicabtagene Ciloleucel and Tisagenlecleucel in Resistant DLBCL: Real-World Matched Comparison
Treatment With Tisagenlecleucel for Infants and Toddlers With B-Cell ALL
Epcoritamab Accepted for Priority Review by FDA in Treatment of LBCL
Role of Novel B-Cell Surface Receptors in the Inhibition of Diffuse Large B-Cell Lymphoma
RAB39B: Potential Prognostic Biomarker of Response to Treatment in DLBCL?
SITC 2022: Identifying Markers for Grade 3 Toxicities in Patients With LBCL Treated With Axicabtagene Ciloleucel
SITC 2022: Anakinra Prophylaxis and Toxicity of Axicabtagene Ciloleucel in Resistant LBCL
ASTRO 2022: Using PET/CT Parameters to Predict Response to Immunotherapy for Diffuse Large B-Cell Lymphoma
ASTRO 2022: Salvage Radiotherapy for Advanced B-Cell NHL After CAR T-Cell Therapy
ASTRO 2022: Can Bridging Radiotherapy Reduce Toxicity of Immunotherapy for Resistant B-Cell Lymphoma?
ASTRO 2022: Does Resistant Large B-Cell Lymphoma Pathology Influence the Efficacy of Radiotherapy?
Is the Endothelial Activation and Stress Index a Potential Prognostic Tool in DLBCL?
ASTRO 2022: Novel Response-Adapted Approach to Treatment of Orbital B-Cell Lymphoma
Tisagenlecleucel Infusion in Lymphoma: Focus on Coagulation and Fibrinolytic Parameters
SOHO 2022: How Does CAR T-Cell Therapy Measure Up to ASCT in Advanced DLBCL?
SEER-Medicare Analysis of Treatment Patterns in Elderly Patients With Mantle Cell Lymphoma
Can Oncogene Expression Be Altered by Super-Enhancer Hypermutation in B-Cell Lymphoma?
SOHO 2022: Clinical Overview of CD20/CD3 Bispecific Antibodies in B-Cell Lymphoma
Novel BTK Inhibitor Under Study in Non–Germinal Center B-Cell–Like DLBCL
ASCO Quality 2022: Long-Term Quality-of-Life Impact of Lisocabtagene Maraleucel in LBCL
CAR T-Cell Therapy Versus Previous Standard of Care for Refractory Aggressive LBCL
ESMO 2022: Novel Antibody-Drug Conjugate Under Study in B-Cell Lymphoma
ESMO 2022: Role of ctDNA in Chinese Patients With Diffuse Large B-Cell Lymphoma
Use of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
ESMO 2022: Can Machine Learning–Based Model Predict DLBCL Subtypes From Whole-Slide Images?
Prognostic Model May Help to Identify Elderly Patients With DLBCL Suited for Chemotherapy
Adding Bortezomib to Standard Treatment in Resistant DLBCL: Final Results From Phase II Trial
Safety and Efficacy of Blinatumomab for Patients With High-Risk DLBCL
BRUIN MCL-321 Focuses on Pirtobrutinib in BTK Inhibitor–Naive Mantle Cell Lymphoma
Zanubrutinib Plus Rituximab: Effective Alternative to R-CHOP in Elderly Patients With DLBCL?
Outcomes After BTK Inhibition in Mantle Cell Lymphoma: View From the United States and Japan
FDA Accepts sBLA for Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Induction Regimens for Older Patients With Mantle Cell Lymphoma
Survey of Oncologists and Hematologists: Considerations in Third-Line Treatment of Follicular Lymphoma
MSI2: Is This RNA-Binding Protein a Potential Therapeutic Target in Mantle Cell Lymphoma?
Pan Pacific 2022: POLARIX Trial of Polatuzumab Vedotin–Based Regimen in DLBCL
Primary Mediastinal LBCL: Closer Look at the Genetic Landscape

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.